12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Company News  |  Deals

arGEN-X deal

arGEN-X granted a second non-exclusive license to an undisclosed company to use arGEN-X's NHance technology to develop and commercialize antibody-based therapeutics. Under...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >